AstraZeneca Stock Nosedives On Mega-Merger Rumor

AstraZeneca (AZN) stock took a nosedive Monday amid reports it's mulling a mega-merger with Bristol Myers Squibb (BMY). The combined company would be worth roughly $400 billion, "making it one of the biggest pharmaceutical mergers in history," RBC Capital Markets analyst Trung Huynh said in a report. The Financial Times first reported the early merger talks. AstraZeneca declined to comment…